
Carlsmed Inc (CARL) Stock Forecast & Price Target
Carlsmed Inc (CARL) Analyst Ratings
Bulls say
Carlsmed Inc. is demonstrating strong financial growth, with a notable 98% increase in third-quarter revenue, reaching $13.1 million, propelled by a significant rise in its surgeon user base, which grew by over 70% year-over-year. The company's gross margin of 75.9% outperformed forecasts, benefiting from reductions in contract manufacturing costs and inventory reserve expenses, indicating operational efficiency. Furthermore, a sustained compound annual growth rate (CAGR) of over 50% in revenue is projected from 2024 to 2028, supported by the expansion into a $13.4 billion U.S. lumbar fusion market and planned advancements into the cervical market.
Bears say
The financial outlook for Carlsmed Inc. is negatively impacted by anticipated revenue challenges, with FY26 estimates for cervical revenue projected at $2.9 million, falling short of the original estimate of $3.4 million due to potential slower adoption of the aprevo platform by new surgeons. Contributing to this unfavorable forecast are several risks, including a lower growth rate within the overall spine market, accelerated degradation of average selling prices, delayed entry into the cervical spine market, and higher-than-expected operating expenses. Additionally, competitive pressures from larger companies and changes in reimbursement policies could further jeopardize Carlsmed's market share and pricing power, with the company experiencing a significant EBITDA loss of $30.7 million.
This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.
Carlsmed Inc (CARL) Analyst Forecast & Price Prediction
Start investing in Carlsmed Inc (CARL)
Order type
Buy in
Order amount
Est. shares
0 shares